Bydureon BCise (Exenatide)

Generic Name

Exenatide

Brand Names

Bydureon BCise, Byetta

FDA approval date: December 10, 2014

Classification: GLP-1 Receptor Agonist

Form: Injection

What is Bydureon BCise (Exenatide)?

Exenatide injection is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Exenatide injection is a glucagon-like peptide-1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Should not be used for the treatment of type 1 diabetes. Has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis. Limitations of Use Exenatide injection is not indicated for use in patients with type 1 diabetes. Exenatide injection contains exenatide and should not be used with other products containing the active ingredient exenatide. Exenatide injection has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis [see Warnings and Precautions.

Approved To Treat

Type 2 Diabetes (T2D)

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

EXCEED - A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

Enrollment Status: Recruiting

Publish Date: October 09, 2025

Intervention Type: Drug

Summary: EXCEED is a non-interventional post-authorisation safety study aiming to assess the risk of developing pancreatic cancer among type 2 diabetes mellitus (T2DM) patients who initiated exenatide compared to those who initiated other non-glucagon like peptide 1 receptor agonists (GLP-1 RA) based glucose lowering drugs (GLDs). Study data will be collected from secondary data sources across 7 European c...

Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University

Enrollment Status: Recruiting

Publish Date: September 18, 2025

Intervention Type: Drug

Study Phase: Not Applicable

Summary: This is a retrospective cohort study of patients with T2DM who were treated with exenatide twice daily as a part of their diabetes care for at least 12 months. The objective of this study is to investigate the influence of T2DM susceptibility gene polymorphisms (NOS1AP, KCNQ1, TCF7L2, WSF1, GLP-1R, etc.) on the efficacy of GLP-1 RA (exenatide, liraglutide, etc.), to identify the variables that can...

Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

Enrollment Status: Recruiting

Publish Date: May 11, 2025

Intervention Type: Drug

Summary: Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensitivity in muscles and weight loss. The mechanisms underpinning the weight loss caused by GLP-1 agoni...

View All Clinical Trials